This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S.
Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries.
1 To qualify for a Breakthrough Device Designation, a device technology must address an unmet need and show that it has the potential to provide for more effective treatment of life-threatening diseases or irreversibly debilitating conditions. Eurointervention; 2023;18-online publish-ahead-of-print January 2023. 2,3 It has shown 99.6%
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. 3 “We very much appreciate FDA’s breakthrough designation recognition of the bioadaptor technology,” continued Sirhan. Food and Drug Administration (FDA). of the U.S.
This launch coincides with the receipt of pass-through status by the CMS, effectiveApril 1, securing a drug-specific Healthcare Common Procedure Coding System (HCPCS) billing code and coverage for traditional Medicare beneficiaries. 2023 Oct, 82 (16) 15981610. Click here to learn more about Flyrcado. link] ii Miller, R. Bednarski, B.
The Office of the National Coordinator for Health Information Technology (ONC) released on July 10 the Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability (HTI-2) proposed rule, building on the HTI-1 final rule released in 2023 and additional information blocking rules released (..)
Implementing the 2023 Expert Consensus Statement: A Strategic Roadmap for Device Manufacturer Sales Representatives In the ever-evolving landscape of cardiac device care, keeping pace with guidelines and policies can often seem daunting.
3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives. 6 Also in 2023, HeartFlow released its RoadMap Analysis which helps identify and quantify narrowings in the coronary arteries and has demonstrated a 25% faster CCTA read time. REVEALPLAQUE Study, SCCT 2023. Data on file.
GLP-1s Are So Hot Right Now – In the year since ACC 2023, GLP-1s went from a weight loss and diabetes drug that “might” have cardiovascular benefits to becoming a promising (and Medicare-covered) option for CV event reduction.
In late 2023, CMS released the 2024 Medicare Physician Fee Schedule (MPFS) Final Rule, ushering in key policy changes for the Quality Payment Program (QPP). MIPS Quality Measurements The Quality performance measure for 2023 includes 30% of the total score.
The following is an edited transcript from an email conversation on April 27, 2023. I learned about the complexities of health insurance – and after several years, I transitioned to the Medicare & Retirement Clinical value team where we worked to reduce the cost of United’s Medicare Advantage plans. Hi Kristie.
v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.
CVD is especially prevalent in the Medicare-aged population, affecting more than 75 percent of those aged 60-79 and more than 90 percent of those aged 80 and over. Participants aged 65+ who enrolled in the Hello Heart app from January through October 2023 were studied retrospectively.
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy. milla1cf Fri, 12/08/2023 - 08:07 December 8, 2023 — Procyrion, Inc. ,
2-4 HeartFlow’s non-invasive FFR CT technology has emerged as a leading frontline strategy for accurately diagnosing hemodynamically significant coronary lesions in patients suspected of having CAD. Longitudinal assessment of safety of FEMOROPOPLITEAL endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries.”
Ensure all Medicare Administrative Contractors (MACs) and health plans are accepting paper claims. The 2023 Merit-based Incentive Payment System (MIPS) data submission window closes on April 1. Encourage the health information technology community to postpone user fees. Waive timely filing deadlines for claims and appeals.
13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. The Lancet.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content